{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:11:27Z","timestamp":1793131887059,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013684","name":"Christie Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jhep.2020.03.007","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T04:06:18Z","timestamp":1583985978000},"page":"170-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":346,"title":["Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract\u00a0cancer"],"prefix":"10.1016","volume":"73","author":[{"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.03.007_bib1","first-page":"e3962","article-title":"Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jhep.2020.03.007_bib2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.03.007_bib3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/gut.48.6.816","article-title":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998","volume":"48","author":"Taylor-Robinson","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.03.007_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2007-1007302","article-title":"Recent advances in the management of cholangiocarcinomas","volume":"14","author":"Vauthey","year":"1994","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2020.03.007_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ctrv.2008.11.009","article-title":"Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions","volume":"35","author":"Anderson","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2020.03.007_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2020.03.007_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.03.007_bib8","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.03.007_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.14090","article-title":"Diagnostic and prognostic biomarkers in cholangiocarcinoma","volume":"39","author":"Macias","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.03.007_bib11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jso.25633","article-title":"Screening high risk populations for cancer: hepatobiliary","volume":"120","author":"Bailey","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"issue":"suppl","key":"10.1016\/j.jhep.2020.03.007_bib14","first-page":"2019","volume":"37","author":"Lamarca","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy","volume":"31","author":"Wang","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib17","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","article-title":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","volume":"29","author":"Wang","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib18","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2017.35.15_suppl.4006","article-title":"Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study","volume":"35","author":"Primrose","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1634\/theoncologist.2012-0432","article-title":"Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues","volume":"17","author":"Zhu","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2020.03.007_bib20","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2020.03.007_bib21","first-page":"57","article-title":"Should patients with resected bile duct cancer receive an adjuvant treatment?","volume":"2","author":"Lamarca","year":"2014","journal-title":"J\u00a0Oncopathol"},{"key":"10.1016\/j.jhep.2020.03.007_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2020.03.007_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2020.03.007_bib24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib25","doi-asserted-by":"crossref","first-page":"e000547","DOI":"10.1136\/esmoopen-2019-000547","article-title":"In the literature: June 2019","volume":"4","author":"Lamarca","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2020.03.007_bib26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","article-title":"Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer","volume":"22","author":"Tsavaris","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jhep.2020.03.007_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000011961","article-title":"Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer","volume":"56","author":"Raderer","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2020.03.007_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/sonc.2002.37380","article-title":"Review of gemcitabine in biliary tract carcinoma","volume":"29","author":"Scheithauer","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A\u00a0phase II study of gemcitabine in gallbladder carcinoma","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","article-title":"Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer","volume":"12","author":"Penz","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/liv.14100","article-title":"Medical treatment for cholangiocarcinoma","volume":"39","author":"Adeva","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.03.007_bib34","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib35","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer","author":"Sakai","year":"2018","journal-title":"ESMO Annual Conference"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib36","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2019.37.15_suppl.4086","article-title":"Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: a phase II trial","volume":"37","author":"Ali","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_8","key":"10.1016\/j.jhep.2020.03.007_bib37","first-page":"viii205","article-title":"A\u00a0new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08). Presented at the ESMO Annual Meeting 2018","volume":"29","author":"McNamara","year":"2018","journal-title":"Ann Oncol"},{"issue":"Supplement_5","key":"10.1016\/j.jhep.2020.03.007_bib38","first-page":"724P","article-title":"Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study","volume":"30","author":"Pape","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib39","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","article-title":"Outcome of second-line chemotherapy for biliary tract cancer","volume":"49","author":"Bridgewater","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","article-title":"Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study","volume":"49","author":"Walter","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib41","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl_8","key":"10.1016\/j.jhep.2020.03.007_bib42","first-page":"viii205","article-title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-_, in Asian patients with pretreated biliary tract cancer: preliminary results from a phase 1 trial","volume":"29","author":"Yoo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis","volume":"41","author":"Al-Adra","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.RVI.0000143768.60751.78","article-title":"Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution","volume":"16","author":"Burger","year":"2005","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jhep.2020.03.007_bib45","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23818","article-title":"Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study","volume":"113","author":"Ibrahim","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib49","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.03.007_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/1096-9098(200102)76:2<121::AID-JSO1022>3.0.CO;2-7","article-title":"Infrequent microsatellite instability in biliary tract cancer","volume":"76","author":"Suto","year":"2001","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib52","first-page":"3156","article-title":"K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China","volume":"8","author":"Rashid","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.03.007_bib53","series-title":"European Cancer Congress 2015, Vienna, Abstract 525","article-title":"Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028","author":"Bang","year":"2015"},{"issue":"suppl_8","key":"10.1016\/j.jhep.2020.03.007_bib54","first-page":"viii205","article-title":"Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase 2 KEYNOTE-158 study. Presented at the ESMO Annual Meeting 2018","volume":"29","author":"Ueno","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib55","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"suppl_5","key":"10.1016\/j.jhep.2020.03.007_bib57","first-page":"mdy149 008","article-title":"A\u00a0phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)","volume":"29","author":"Richard","year":"2018","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib58","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1200\/JCO.2018.36.15_suppl.4087","article-title":"Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): clinical outcomes and biomarker analyses","volume":"36","author":"Kelley","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib60","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib62","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib64","series-title":"Gastrointestinal Cancers Symposium Annual Meeting; 2015; San Francisco, CA","article-title":"A\u00a0phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma","author":"Goyal","year":"2015"},{"key":"10.1016\/j.jhep.2020.03.007_bib65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12885-016-2174-8","article-title":"A\u00a0phase 1b study of selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study","volume":"16","author":"Bridgewater","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib66","doi-asserted-by":"crossref","first-page":"12122","DOI":"10.1038\/srep12122","article-title":"Results of an abbreviated phase-II study with the Akt inhibitor MK-2206 in patients with advanced biliary cancer","volume":"5","author":"Ahn","year":"2015","journal-title":"Sci Rep"},{"issue":"suppl","key":"10.1016\/j.jhep.2020.03.007_bib67","first-page":"5s","article-title":"Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol. 2014 ASCO Annual Meeting","volume":"32","author":"Yeung","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib68","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A\u00a0phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2020.03.007_bib69","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","article-title":"HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2020.03.007_bib70","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A\u00a0KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib71","series-title":"Presented at: 2019 Gastrointestinal Cancers Symposium; January 17\u201319, 2019; San Francisco Abstract 345","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: a randomized double-blinded placebo-controlled phase II trial","author":"Demols","year":"2019"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2020.03.007_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.2020.38.4_suppl.477","article-title":"Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): a randomized, double-blind, phase II study","volume":"38","author":"Valle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/cb500996u","article-title":"Small molecule inhibitors of bromodomain-acetyl-lysine interactions","volume":"10","author":"Brand","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jhep.2020.03.007_bib75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","article-title":"Biliary tract cancer: state of the Art and potential role of DNA damage repair","volume":"70","author":"Lamarca","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2020.03.007_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib77","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.03.007_bib78","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1073\/pnas.1508113112","article-title":"Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia","volume":"112","author":"Koo","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2020.03.007_bib79","doi-asserted-by":"crossref","first-page":"e0206007","DOI":"10.1371\/journal.pone.0206007","article-title":"The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers","volume":"13","author":"Lamarca","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.03.007_bib80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multi-targeted pan-TRK, ROS1, and ALK inhibitor entrectinib (RXDX-101): combined results from two phase 1 trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2020.03.007_bib82","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.03.007_bib83","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.03.007_bib84","doi-asserted-by":"crossref","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jhep.2020.03.007_bib85","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1053\/j.gastro.2014.01.062","article-title":"Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients","volume":"146","author":"Gao","year":"2014","journal-title":"Gastroenterology"},{"issue":"3_suppl","key":"10.1016\/j.jhep.2020.03.007_bib86","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/jco.2015.33.3_suppl.285","article-title":"Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets","volume":"33","author":"Holcombe","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib87","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/jco.2015.33.15_suppl.4009","article-title":"Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations","volume":"33","author":"Ross","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib88","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib89","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.03.007_bib90","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2020.03.007_bib91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-016-0432-2","article-title":"Genomic profiling of biliary tract cancers and implications for clinical practice","volume":"17","author":"Jain","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib92","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.03.007_bib93","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib94","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1200\/JCO.2019.37.15_suppl.4087","article-title":"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH)","volume":"37","author":"Javle","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib95","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib96","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2020.03.007_bib97","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/ncomms7120","article-title":"Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2020.03.007_bib98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jhep.2020.03.007_bib99","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.03.007_bib100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.01.005","article-title":"HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting","volume":"143","author":"Kol","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.03.007_bib102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2020.03.007_bib103","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccr.2013.04.012","article-title":"Oncogenic ERBB3 mutations in human cancers","volume":"23","author":"Jaiswal","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2020.03.007_bib104","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2020.03.007_bib105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2407-11-60","article-title":"Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma","volume":"11","author":"Deshpande","year":"2011","journal-title":"BMC Cancer"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib106","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1200\/JCO.2019.37.15_suppl.4080","article-title":"Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma","volume":"37","author":"Silverman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib107","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2020.03.007_bib109","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2020.03.007_bib110","series-title":"Essentials of Medical Biochemistry","author":"Bhagavan","year":"2011"},{"key":"10.1016\/j.jhep.2020.03.007_bib111","first-page":"171","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib112","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-13-2649","article-title":"Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma","volume":"20","author":"Borger","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.03.007_bib113","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib114","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2020.03.007_bib115","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib116","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2020.03.007_bib117","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2020.03.007_bib118","doi-asserted-by":"crossref","first-page":"8946","DOI":"10.1038\/s41598-019-45346-1","article-title":"Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers","volume":"9","author":"Unruh","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2020.03.007_bib119","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jhep.2020.03.007_bib120","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jhep.2020.03.007_bib121","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib122","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1111\/bcp.14105","article-title":"New drugs approved for acute myeloid leukaemia in 2018","volume":"85","author":"Kucukyurt","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2020.03.007_bib123","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10637-019-00771-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","volume":"38","author":"Fan","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jhep.2020.03.007_bib124","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl_5","key":"10.1016\/j.jhep.2020.03.007_bib125","first-page":"v851","article-title":"ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs. placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation","volume":"30","author":"Abou-Alfa","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib126","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib128","doi-asserted-by":"crossref","first-page":"12851","DOI":"10.1073\/pnas.1817662116","article-title":"2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation","volume":"116","author":"Schvartzman","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2020.03.007_bib129","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.03.007_bib130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.03.007_bib131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.03.007_bib132","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast\u00a0growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.03.007_bib133","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.03.015","article-title":"Targeting the fibroblast growth factor receptor family in cancer","volume":"46","author":"Hallinan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2020.03.007_bib134","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2012.07.001","article-title":"Anticancer molecules targeting fibroblast growth factor receptors","volume":"33","author":"Liang","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jhep.2020.03.007_bib135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib136","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib137","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2020.03.007_bib138","first-page":"1","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib139","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib140","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2017.35.15_suppl.4017","article-title":"ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. ASCO Annual Meeting 2017","volume":"35","author":"Mazzaferro","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib141","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2020.03.007_bib142","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2020.03.007_bib143","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cmdc.201700718","article-title":"Discovery of Rogaratinib (BAY 1163877): a pan-FGFR inhibitor","volume":"13","author":"Collin","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jhep.2020.03.007_bib144","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A\u00a0phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer","volume":"12","author":"Michael","year":"2017","journal-title":"Target Oncol"},{"issue":"suppl_8","key":"10.1016\/j.jhep.2020.03.007_bib145","first-page":"viii205","volume":"29","author":"Hollebecque","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"10.1016\/j.jhep.2020.03.007_bib146","first-page":"v851","article-title":"FIGHT-202: a phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl_8","key":"10.1016\/j.jhep.2020.03.007_bib147","doi-asserted-by":"crossref","first-page":"viii720","DOI":"10.1093\/annonc\/mdy424.030","article-title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions","volume":"29","author":"Javle","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"10.1016\/j.jhep.2020.03.007_bib148","first-page":"mdy149","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. ESMO Annual Meeting 2018","volume":"29","author":"Meric-Bernstam","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl_9","key":"10.1016\/j.jhep.2020.03.007_bib149","first-page":"ix46","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's","volume":"29","author":"Tran","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2020.03.007_bib151","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2018.36.4_suppl.447","article-title":"safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC)","volume":"36","author":"Cleary","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.03.007_bib152","doi-asserted-by":"crossref","first-page":"AB065","DOI":"10.21037\/hbsn.2019.AB065","article-title":"Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results","volume":"8","author":"Ng","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhep.2020.03.007_bib153","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.03.007_bib154","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2017.35.15_suppl.4074","article-title":"Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA)","volume":"35","author":"Soria","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib156","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhep.2020.03.007_bib157","doi-asserted-by":"crossref","first-page":"a004002","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.jhep.2020.03.007_bib158","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.18632\/oncotarget.14788","article-title":"Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2020.03.007_bib159","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works","volume":"18","author":"Liu","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2020.03.007_bib160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"Wohrle","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jhep.2020.03.007_bib161","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"Wohrle","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jhep.2020.03.007_bib163","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A\u00a0phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.03.007_bib164","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2217\/fon-2019-0141","article-title":"Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design","volume":"15","author":"Catenacci","year":"2019","journal-title":"Future Oncol"},{"issue":"11 Supplement","key":"10.1016\/j.jhep.2020.03.007_bib165","first-page":"B55","article-title":"FP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth\u00a0and angiogenesis","volume":"6","author":"Zhang","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2020.03.007_bib166","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A\u00a0phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib167","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib168","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2020.03.007_bib169","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","article-title":"FGF401, A first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer","volume":"18","author":"Weiss","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2020.03.007_bib170","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1039\/C9CC02052G","article-title":"Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4","volume":"55","author":"Zhou","year":"2019","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.jhep.2020.03.007_bib171","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhep.2020.03.007_bib172","first-page":"743193","article-title":"The HER2 receptor in breast cancer: Pathophysiology, clinical Use, and new advances in therapy","volume":"2012","author":"Mitri","year":"2012","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.jhep.2020.03.007_bib173","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br J Cancer"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2020.03.007_bib174","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2017.35.4_suppl.402","article-title":"Pertuzumab\u00a0+ trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway","volume":"35","author":"Javle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib175","series-title":"ESMO World Congress on GI Cancer 2019, abstract O-005","article-title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT \u2018basket\u2019 trial","author":"Harding","year":"2019"},{"key":"10.1016\/j.jhep.2020.03.007_bib176","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbrc.2010.11.082","article-title":"RNF43 interacts with NEDL1 and regulates p53-mediated transcription","volume":"404","author":"Shinada","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2020.03.007_bib177","doi-asserted-by":"crossref","first-page":"ra90","DOI":"10.1126\/scisignal.aac6757","article-title":"The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated beta-catenin by sequestering TCF4 to the nuclear membrane","volume":"8","author":"Loregger","year":"2015","journal-title":"Sci Signal"},{"key":"10.1016\/j.jhep.2020.03.007_bib178","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2020.03.007_bib179","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib181","doi-asserted-by":"crossref","first-page":"e15640","DOI":"10.1371\/journal.pone.0015640","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.03.007_bib182","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","article-title":"Cholangiocarcinoma heterogeneity revealed by Multigene mutational profiling: clinical and prognostic relevance in surgically resected patients","volume":"23","author":"Ruzzenente","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2020.03.007_bib183","series-title":"2019 Gastrointestinal Cancers Symposium Abstract 187","article-title":"Efficacy and safety of dabrafenib and trametinib in patients with BRAF V600E-mutated biliary tract cancer: a cohort of the ROAR basket trial","author":"Wainberg","year":"2019"},{"key":"10.1016\/j.jhep.2020.03.007_bib184","doi-asserted-by":"crossref","first-page":"13261","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2020.03.007_bib185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5858\/arpa.2016-0096-OA","article-title":"Improving adequacy of small biopsy and fine-needle aspiration specimens for molecular testing by next-generation sequencing in patients with Lung cancer: a quality improvement study at Dartmouth-Hitchcock medical center","volume":"141","author":"Padmanabhan","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jhep.2020.03.007_bib186","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the\u00a0ABC-01, -02 and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2020.03.007_bib187","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820301653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820301653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T15:19:52Z","timestamp":1716650392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820301653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0168827820301653"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.03.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract\u00a0cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}